Zevra Therapeutics (ZVRA) Net Cash Flow Growth (3y) (2017 - 2026)
Zevra Therapeutics (ZVRA) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Zevra Therapeutics |
796.95 Mn |
596.33 Mn |
34.30 Mn |
48.88% |
| Date | Value |
|---|
| Mar 31, 2026 |
48.88% |
| Dec 31, 2025 |
55.13% |
| Sep 30, 2025 |
43.89% |
| Jun 30, 2025 |
32.87% |
| Mar 31, 2025 |
36.27% |
| Dec 31, 2024 |
-2.99% |
| Sep 30, 2024 |
177.11% |
| Jun 30, 2024 |
-27.43% |
| Mar 31, 2024 |
-26.04% |
| Dec 31, 2023 |
20.47% |
| Sep 30, 2023 |
-174.63% |
| Jun 30, 2023 |
87.10% |
| Mar 31, 2023 |
-192.50% |
| Dec 31, 2022 |
-11.46% |
| Sep 30, 2022 |
-104.97% |
| Jun 30, 2022 |
-65.77% |
| Mar 31, 2022 |
-12.83% |
| Dec 31, 2021 |
-47.06% |
| Sep 30, 2021 |
62.24% |
| Jun 30, 2021 |
93.66% |
